Nanobiotix S.A. American Depositary Shares (NBTX) Financials
Key financial figures for Nanobiotix S.A. American Depositary Shares (Q2 2026), as reported in EUR.
Nanobiotix S.A. reported revenue of 5.6 million EUR for Q2 FY2026, down 40.2% from the same period a year earlier. The company posted a net loss of 34.7 million EUR, or -0.71 EUR per share. Operating margin came to -322.9%, against -254.62% a year earlier. Free cash flow for the period was -23.0 million EUR. Across the last 5 reported quarters, quarterly revenue has moved from 9.3 million EUR in Q2 FY2024 to 5.6 million EUR in Q2 FY2026. The figures above are as filed, and the full income statement, balance sheet and cash flow history for Nanobiotix S.A. are on the SentiSense financials page.
- Revenue
- EUR 6M
- Net Income
- -EUR 35M
- EPS
- EUR -0.71
- Total Assets
- EUR 128M
- Operating Cash Flow
- -EUR 22M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | EUR 6M | -EUR 35M | -EUR 0.71 | -322.9% | -EUR 23M |
| Q4 FY2025 | EUR 3M | -EUR 19M | -EUR 0.39 | -386.89% | -EUR 16M |
| Q2 FY2025 | EUR 27M | -EUR 5M | -EUR 0.11 | 3.03% | -EUR 18M |
| Q4 FY2024 | -EUR 16M | -EUR 46M | -EUR 0.98 | -EUR 14M | |
| Q2 FY2024 | EUR 9M | -EUR 22M | -EUR 0.46 | -254.62% | -EUR 6M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | EUR 30M | -EUR 24M | -EUR 0.50 | -36.49% | -EUR 34M |
| FY2024 | -EUR 7M | -EUR 68M | -EUR 1.44 | -EUR 20M | |
| FY2023 | EUR 36M | -EUR 40M | -EUR 1.08 | -73.96% | -EUR 13M |
Frequently asked questions
What was Nanobiotix S.A.'s revenue last quarter?
Nanobiotix S.A. reported revenue of 5.6 million EUR for Q2 FY2026, down 40.2% from the same period a year earlier.
Is Nanobiotix S.A. profitable?
Not in its most recent reported period. Nanobiotix S.A. reported a net loss of 34.7 million EUR for Q2 FY2026, a net margin of -626.01% on revenue.
How has Nanobiotix S.A.'s margin trended?
Operating margin was -322.9% in Q2 FY2026, compared with -254.62% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Nanobiotix S.A. generate?
Nanobiotix S.A. generated free cash flow of -23.0 million EUR in Q2 FY2026, after capital expenditure.
Figures are as reported by the filer in EUR and are not converted to US dollars. The share price is quoted in US dollars, so the two are not directly comparable.
Full income statement, balance sheet and cash flow for Nanobiotix S.A. American Depositary Shares on SentiSense, with up to forty quarters and twenty fiscal years of history.